NCT05778071: An ongoing trial by Alexion Pharmaceuticals, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05778071 |
|---|---|
| Title | A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 7, 2023 |
| Completion date | Nov. 15, 2024 |
| Required reporting date | Nov. 15, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |